Shay Capital’s Novo Nordisk NVO Stock Holding History

Shay Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,500	Closed	-$536K	–	388
2024 Q3	$536K	Buy	+4,500	New	+$600K	0.08%	154
2024 Q2	–	Sell	-2,000	Closed	-$257K	–	382
2024 Q1	$257K	Buy	+2,000	New	+$238K	0.04%	273

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Shay Capital's NVO Position: Q4 2024 in Review

Shay Capital sold out of Novo Nordisk (NVO) in Q4 2024, closing a stake of 3,634 shares — an estimated $433K sold.

Shay Capital first reported a position in NVO in Q1 2021 and held it in 6 quarters. The position peaked at $2.41M in Q2 2024. 1,663 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

Shay Capital reported no remaining Novo Nordisk position as of Q4 2024 after selling out during the quarter.
Shay Capital sold 3,634 Novo Nordisk shares in Q4 2024, an estimated $433K.
Shay Capital first reported a position in Novo Nordisk in Q1 2021 and held it in 6 quarters.
Shay Capital's Novo Nordisk position peaked at $2.41M in Q2 2024.
1,663 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on Shay Capital's 13F filing for Q4 2024, filed 14 Feb 2025.